Review
Gastroenterology & Hepatology
Yamini Natarajan, Aylin Tansel, Parth Patel, Kingsley Emologu, Richa Shukla, Zeeshan Qureshi, Hashem B. El-Serag, Aaron P. Thrift, Fasiha Kanwal
Summary: The risk factors for hepatocellular carcinoma (HCC) in patients with primary biliary cholangitis (PBC) are not clear, but cirrhosis and male gender are shown to be significant factors in increasing HCC incidence. Further studies are needed to evaluate additional risk factors in this population and support current recommendations for HCC surveillance in PBC patients with cirrhosis.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Gastroenterology & Hepatology
K. Rajender Reddy, Dale McLerran, Tracey Marsh, Neehar Parikh, Lewis R. Roberts, Myron Schwartz, Mindie H. Nguyen, Alex Befeler, Stephanie Page-Lester, Runlong Tang, Sudhir Srivastava, Jo Ann Rinaudo, Ziding Feng, Jorge A. Marrero
Summary: This is the largest prospective and geographically diverse study of a U.S. cohort of patients with cirrhosis, validating known risk factors for HCC.
Article
Gastroenterology & Hepatology
Ji H. Nahm, Hye S. Lee, Haeryoung Kim, Sun Y. Yim, Ji-hyun Shin, Jeong E. Yoo, Sang H. Ahn, Jin S. Choi, Ju-Seog Lee, Young N. Park
Summary: This study developed a nomogram for predicting late recurrence of hepatocellular carcinoma (HCC) based on clinicopathological and molecular factors. The combination of pSTAT3, pERK1/2 and SYK immunoexpression with high lobular inflammatory activity and cirrhosis was found to predict late HCC recurrence.
LIVER INTERNATIONAL
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Atanas Pachev, Lucas Rauyaud, Luisa Paulatto, Marco Dioguardi Burgio, Vincent Roche, Carmela Garcia Alba, Annie Sibert, Matthieu Lagadec, Juliette Kavafyan-Lasserre, Catherine Paugam-Burtz, Valerie Vilgrain, Maxime Ronot
Summary: Severe abdominal pain was frequent during and after TACE for hepatocellular carcinoma. Young patients without alcoholic liver disease or cirrhosis may benefit from reinforced analgesia.
EUROPEAN RADIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Grace Lai-Hung Wong, Vicki Wing-Ki Hui, Terry Cheuk-Fung Yip, Lilian Yan Liang, Xinrong Zhang, Yee-Kit Tse, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong
Summary: Universal HBV vaccination markedly reduces the prevalence of chronic HBV infection and may contribute to the decreased incidences of HCC and hepatic events.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Gastroenterology & Hepatology
Daniel Q. Huang, Darren J. H. Tan, Cheng Han Ng, Maral Amangurbanova, Nancy Sutter, Phoebe Wen Lin Tay, Wen Hui Lim, Jie Ning Yong, Ansel Tang, Nicholas Syn, Mark D. Muthiah, Eunice X. X. Tan, Shravan Dave, Benjamin Tay, Abdul M. Majzoub, Danielle Gerberi, Beom Kyung Kim, Rohit Loomba
Summary: A pooled analysis of time-to-event data revealed that the incidence of hepatocellular carcinoma (HCC) in alcohol-associated cirrhosis is significant, with cumulative risks of 3% and 9% at 5 and 10 years, respectively.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Alexander M. Sy, Raphaella D. Ferreira, Binu V. John
Summary: Several studies have shown that patients with PBC have an increased risk of developing HCC. Risk factors for HCC in PBC include advanced age, male sex, comorbidities, and advanced liver fibrosis. The role of treatment response as a risk factor for HCC development in PBC patients should be further investigated. HCC in PBC has a poor prognosis compared to other chronic liver diseases with HCC, and liver transplantation offers the highest survival rate among available therapies.
CLINICS IN LIVER DISEASE
(2022)
Article
Multidisciplinary Sciences
Tomomi Kogiso, Takaomi Sagawa, Makiko Taniai, Eriko Shimada, Kei Inai, Tokuko Shinohara, Katsutoshi Tokushige
Summary: This study found that the complication of polysplenia and a higher MELD-XI score may be independent risk factors for the development of hepatocellular carcinoma (HCC) in patients with Fontan-associated liver disease (FALD), and patients with these risk factors tend to have a poor prognosis.
Article
Biochemistry & Molecular Biology
Naohiro Nakamura, Katsunori Yoshida, Rinako Tsuda, Miki Murata, Takashi Yamaguchi, Kanehiko Suwa, Mayuko Ichimura, Koichi Tsuneyama, Koichi Matsuzaki, Toshiaki Nakano, Junko Hirohara, Toshihito Seki, Kazuichi Okazaki, M. Eric Gershwin, Makoto Naganuma
Summary: Patients with primary biliary cholangitis (PBC) are at higher risk for developing hepatocellular carcinoma (HCC), especially in the presence of comorbidities like excessive alcohol consumption. This study found that the balance of Smad signals may serve as a biomarker to predict the likelihood of HCC occurrence in PBC patients. Shifting favorably Smad phospho-isoforms through therapies could potentially reduce the risk of PBC-related HCC development.
FRONTIERS IN BIOSCIENCE-LANDMARK
(2021)
Article
Gastroenterology & Hepatology
Christian S. Alvarez, Jessica L. Petrick, Dominick Parisi, Brian J. McMahon, Barry Graubard, Katherine A. McGlynn
Summary: This study examined the incidence and mortality rates of HCC in the USA between 1992 and 2018, finding that rates began to decline for most groups starting in 2015, although disparities continued to exist. The study highlighted that greater efforts are needed to reduce the burden of HCC among vulnerable groups such as non-Hispanic Black individuals and American Indians/Alaska Natives.
Article
Gastroenterology & Hepatology
Mark R. Pedersen, Garrett Greenan, Sumant Arora, Arvind R. Murali, Marlyn J. Mayo
Summary: UDCA after LT reduces the odds of BC and bile stones and sludge in all-comer LT recipients and reduces or delays the incidence of rPBC in patients transplanted for PBC. UDCA use after LT could be considered in all LT recipients to reduce the odds of BC and may be particularly beneficial for patients transplanted for PBC by reducing the incidence of rPBC.
LIVER TRANSPLANTATION
(2021)
Article
Gastroenterology & Hepatology
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang
Summary: This study investigated the frequency and associated factors of unrecognized cirrhosis in patients with hepatocellular carcinoma (HCC) in the United States. The results showed that more than half of the patients with cirrhosis were not diagnosed in a timely manner, especially among those with NAFLD-related HCC. Male sex, non-Hispanic Black race, and NAFLD etiology were associated with unrecognized cirrhosis. Unrecognized cirrhosis was associated with worse overall survival.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Nutrition & Dietetics
Maryam Ebadi, Stephen Ip, Ellina Lytvyak, Somayyeh Asghari, Elora Rider, Andrew Mason, Aldo J. Montano-Loza
Summary: This study aims to investigate the prevalence of vitamin D deficiency in patients with primary biliary cholangitis (PBC) and its impact on treatment response to ursodeoxycholic acid (UDCA), development of cirrhosis, and liver-related events (mortality and liver transplantation).
Article
Oncology
Chern-Horng Lee, Chiu-Yi Hsu, Tzung-Hai Yen, Tsung-Han Wu, Ming-Chin Yu, Sen-Yung Hsieh
Summary: This study aimed to assess the efficacy and safety of long-term aspirin use in cirrhotic patients. The results showed that long-term aspirin use significantly reduced the incidence of hepatocellular carcinoma and overall mortality, without increasing the risk of gastrointestinal bleeding.
Article
Gastroenterology & Hepatology
Julian Hercun, Mazen Noureddin, Nabil Noureddin, Jason Eccleston, Daniel Woolridge, T. Jake Liang, Michele Tana, David E. Kleiner, Gracia Viana Rodriguez, Christopher Koh, Jay H. Hoofnagle, Theo Heller
Summary: This study evaluated the involvement of bile duct and disease progression in patients with primary biliary cholangitis (PBC) and found that bile duct injury does not follow the same course as fibrosis, and certain indicators are associated with ductopenia progression.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)